Drug intelligence / Profile preview

GS-2121

Development stage: Phase 1
Lead developer: Gilead Sciences
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

GS-2121 is an orally administered small molecule investigational antineoplastic agent developed by Gilead Sciences. It is currently in Phase 1 clinical trials for the treatment of advanced solid tumors, being evaluated both as a monotherapy and in combination with zimberelimab, an anti-PD-1 antibody. The precise mechanism of action and molecular targets of GS-2121 have not been publicly disclosed. The ongoing first-in-human study aims to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in adults with advanced malignancies who have progressed on or are intolerant to standard therapies[3][5][7].

Beyond the preview

Go deeper on GS-2121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-2121.

Explore the full profile